Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sym004 in Recurrent/Metastatic SCCHN
NCT01417936Phase 2Completed
- Sponsor
- Symphogen
- Start
- Jul 2011
- Primary completion
- Oct 2012
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of futuximab + modotuximab in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Symphogen. Started Jul 2011; status: completed.
02
Drugs
futuximab + modotuximab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT01417936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01417936.